Immunotherapy – Talk Bio

Candel Therapeutics Showcases Immunotherapy Leadership at SITC 2025, Highlighting Integration of Clinical Innovation, Multi-Omics, and AI for Solid Tumor Therapies

5 days ago talkbio0Tagged Artificial Intelligence, CAN-2409, Candel Therapeutics, enLIGHTEN Discovery Platform, Immunotherapy, Malignant neoplasm of prostate, Multiomics, Non-Small Cell Lung Carcinoma, Precision Medicine, SITC, Solid Neoplasm

Candel Therapeutics; SITC 2025; immunotherapy; CAN-2409; multi-omics; artificial intelligence; solid tumors; enLIGHTEN Discovery Platform; prostate cancer; non-small cell lung cancer; precision medicine

ESMO 2025 KEYNOTE-671 Update: Perioperative Pembrolizumab Reinforces NSCLC Standard

1 week ago talkbio0Tagged ESMO Congress, Event-Free Survival, Immunotherapy, KEYNOTE-671, Keytruda, Non-Small Cell Lung Carcinoma, Overall Survival, pembrolizumab, perioperative, Standard of Care

KEYNOTE-671; pembrolizumab; KEYTRUDA; perioperative immunotherapy; NSCLC; overall survival; event-free survival; ESMO Congress; standard of care

Ipsen to Acquire ImCheck Therapeutics for €350 Million to Expand Immunotherapy Pipeline

3 weeks ago talkbio0Tagged Acquisition, Anti-BTN3A Agonistic Monoclonal Antibody ICT01, BTN3A, butyrophilin superfamily, ImCheck Therapeutics, Immunotherapy, Ipsen, Leukemia, Myelocytic, Acute, Monoclonal Antibodies, Oncology Pipeline

Ipsen; ImCheck Therapeutics; acquisition; €350 million; €1 billion deal; immunotherapy; oncology pipeline; butyrophilin superfamily; ICT01; acute myeloid leukemia; monoclonal antibody; BTN3A

Lunit AI Predicts Immunotherapy Outcomes in Colorectal, Kidney, and Lung Cancer at ESMO 2025

4 weeks ago talkbio0Tagged Biological Markers, Colorectal Carcinoma, Immunotherapy, Lunit AI, Malignant neoplasm of kidney, Malignant neoplasm of lung, Pathology, SCOPE IO, treatment prediction

Lunit AI; SCOPE IO; immunotherapy; colorectal cancer; kidney cancer; lung cancer; biomarkers; ESMO 2025; treatment prediction; AI pathology

Moderna Unveils Promising mRNA-4359 Cancer Antigen Therapy Data in Melanoma Ahead of ESMO 2025

4 weeks ago talkbio0Tagged cancer antigen therapy, checkpoint inhibitor-resistant, disease control rate, Frequency of Responses, IDO1, Immunotherapy, melanoma, Moderna, mRNA-4359, PD-L1, pembrolizumab, Phase 1/2 trial

Moderna; mRNA-4359; cancer antigen therapy; melanoma; ESMO 2025; checkpoint inhibitor-resistant; PD-L1; IDO1; objective response rate; disease control rate; immunotherapy; Phase 1/2 trial; pembrolizumab

AstraZeneca and Daiichi Sankyo Report Landmark Results for Datroway in Triple-Negative Breast Cancer

1 month ago talkbio0Tagged ADC, AstraZeneca, Clinical Trials, Daiichi, Datopotamab deruxtecan, Datroway, Immunotherapy, Overall Survival, Pharmacotherapy, Phase 3 trial, Sankyo, therapeutic autologous dendritic cells, Triple Negative Breast Neoplasms, TROPION-Breast02

Datroway; Datopotamab deruxtecan; triple-negative breast cancer; ADC; AstraZeneca; Daiichi Sankyo; clinical trial; overall survival; chemotherapy; TROP2; phase 3 trial; immunotherapy; TROPION-Breast02

FDA Grants Full Approval to Precigen’s Papzimeos for Rare Disease RRP

3 months ago talkbio0Tagged Approved, Episodic, gene therapy, Immunotherapy, Infrequent, orphan drug designation, Papzimeos, Precigen, Recurrent respiratory papillomatosis, RRP, United States Food and Drug Administration

Precigen; Papzimeos; FDA approval; recurrent respiratory papillomatosis (RRP); gene therapy; immunotherapy; rare disease; Orphan Drug designation

Precigen Receives FDA Approval for First Immunotherapy for HPV-Related Recurrent Respiratory Papillomatosis

3 months ago talkbio0Tagged Adenovirus Vector, Approved, Episodic, gene therapy, human papillomavirus, Identifier, Immunotherapy, Papzimeos, Precigen, Recurrent respiratory papillomatosis, RRP, United States Food and Drug Administration, zopapogene imadenovec-drba

Precigen; FDA approval; Papzimeos; zopapogene imadenovec-drba; HPV; recurrent respiratory papillomatosis (RRP); immunotherapy; gene therapy; adenoviral vector; Breakthrough Therapy designation

Dispatch Bio Launches with $216M and CAR-T Pioneer Carl June to Advance Universal Solid Tumor Immunotherapy

4 months ago talkbio0Tagged Arch of foot, Cancer Therapeutic Procedure, CAR-T, Carl June, Dispatch Bio, Flare platform, Funding, Immunotherapy, Parker Institute for Cancer Immunotherapy, Partner in relationship, Series, Solid Neoplasm, venture

Dispatch Bio; solid tumors; immunotherapy; CAR-T; Carl June; Series A funding; Flare platform; Parker Institute for Cancer Immunotherapy; ARCH Venture Partners; universal cancer treatment

Scancell’s Cancer Vaccine Supercharges Melanoma Immunotherapy in Recent Trials

4 months ago talkbio0Tagged Cancer Vaccines, checkpoint inhibitors, Clinical Trials, Immunotherapy, iSCIB1 +, melanoma, Melanoma TRP2 CTL Epitope Vaccine SCIB1, Scancell, SCOPE trial

Scancell; SCIB1; iSCIB1+; melanoma; cancer vaccine; immunotherapy; checkpoint inhibitors; clinical trial; SCOPE trial